Table 1.
Patient characteristics
| Characteristic | Population (N = 86) |
|---|---|
| N (%) | |
| Age (years) | |
| Median | 65 |
| Range | 20–87 |
| Male gender | 47 (54.6) |
| ECOG performance status | |
| 0–1 | 57 (66.3) |
| 2 | 29 (33.7) |
| Histology | |
| DLBCL | 67 (77.9) |
| FL grade III | 8 (9.3) |
| PTCL | 3 (3.5) |
| ALCL | 3 (3.5) |
| MCL | 2 (2.3) |
| MZL | 2 (2.3) |
| BL | 1 (1.2) |
| Stage | |
| I | 12 (14.0) |
| II | 16 (18.6) |
| III | 29 (33.7) |
| IV | 29 (33.7) |
| Chemotherapy regimen | |
| R-CHOP | 40 (46.5) |
| CHOP | 24 (27.9) |
| R-COMP | 13 (15.1) |
| Othera | 9 (10.5) |
DLBCL diffuse large B cell lymphoma, FL follicular lymphoma, PTCL peripheral T cell lymphoma, ALCL anaplastic large cell lymphoma, MCL mantle cell lymphoma, MZL marginal zone lymphoma, BL Burkitt's lymphoma, CHOP cyclophosphamide, doxorubicin, vincristine, prednisone, R-CHOP rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone, R-COMP rituximab, cyclophosphamide, vincristine, liposomal doxorubicin, prednisone
aDoxorubicin based regimen